Immunogen (IMGN) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
ImmunoGen Reports Pipeline Progress and 2017 Operating Results
February 9, 2018 6:30 AM ESTSignificant Operational and Financial Progress in 2017 with a Robust Set of Data and Events Expected in 2018
Mirvetuximab Soravtansine Phase 3 FORWARD I Trial to Complete Enrollment by Mid-Year; FORWARD II Combination Data to be Presented Throughout 2018
Novel ADC Pipeline Continues to Advance with Patients Enrolling in Phase 1 Study of IMGN632 and Phase 1 Data Presented at ASH for IMGN779
Conference Call to be Held at 8:00 a.m. ET Today
WALTHAM, Mass.--(BUSINESS WIRE)--... More
